SAB Biotherapeutics Archives - Page 2 of 6

Meet South Dakota couple who became quiet force behind state’s newest public company

“The future is as big as you can imagine.” And they helped make it so. Meet the local couple behind this incredible startup success story.

2 years ago

SAB goes public in listing on Nasdaq

Sioux Falls-based SAB Biotherapeutics officially is a publicly traded company.

2 years ago

SAB moves to next phase with COVID therapeutic

Based on data that shows it’s safe and effective, the COVID-19 therapeutic developed by Sioux Falls-based SAB Biotherapeutics has moved into phase three of clinical trials.

3 years ago

SAB awarded $60M more in government funding for COVID-19 therapeutic

The federal government has awarded additional funding of $60.5 million to Sioux Falls-based SAB Biotherapeutics as it advances its treatment for COVID-19.

3 years ago

Behind the scenes of a deal that could catapult this local biotech company to big things

“We see this as a one-of-a-kind opportunity, and it stood out.” Out of 60 companies, how a Sioux Falls biotech business became the one to take public.

3 years ago

SAB’s therapeutic shows promising results against Delta, other variants

The treatment developed by Sioux Falls-based SAB Biotherapeutics for the virus that causes COVID-19 has shown “effective and potent” ability to neutralize multiple variants of concern, including the Delta and Lambda variants.

3 years ago